Characteristics of Hematopoitic Growth Factor, G-CSF and Its Clinical Vision |
Park, Jeong-Hae
(Department of Clinical Laboratory Science, Dong Eui University)
Park, Jung-Ae (Department of Clinical Laboratory Science, Dong Eui University) Kang, Seok-Woo (Department of Agricultural Biology, National Academy of Agricultural Science, RDA) Goo, Tae-Won (Department of Agricultural Biology, National Academy of Agricultural Science, RDA) Chung, Kyung-Tae (Department of Clinical Laboratory Science, Dong Eui University) |
1 | Scrip Report. 2007. Biosimilar, Biogenerics and Follow-on Biologics. Informa UK Ltd. (http://www.scripintelligence.com/multimedia/archive/00000/BS1342_117a.pdf) |
2 | Smith, L., C. Redfield, J. Boyd, G. Lawrence, R. Edwards, R. Smith, and C. Dobson. 1992. Human interleukin 4. The solution structure of a four-helix bundle protein. J. Mol. Biol. 224, 899-904. DOI |
3 | Sourgens, H. and F. Lefrere. 2011. A systematic review of available clinical evidence-filgrastim compared with lenograstim. Int. J. Clin. Pharmacol. Ther. 49, 510-518. DOI |
4 | Nissen, C. 1994. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur. J. Cancer 30A, S12-14. |
5 | Oh-eda, M., M. Hasegawa, K. Hattori, H. Kuboniwa, T. Kojima, T. Orita, K. Tomonou, T. Yamazaki, and N. Ochi. 1990. O-linked sugar chain of human granulocyte colony- stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J. Biol. Chem. 265, 11432-11435. |
6 | Ono, M., M. Oh-eda, S. Kamachi, M. Kato, Y. Endo, and N. Ochi. 1992. Structure of G-CSF: significance of the sugar chain. J. Nutr. Sci. Vitaminol. (Tokyo) Spec No, 337-340. |
7 | Ono, M. 1994. Physicochemical and biochemical characteristics of glycosylatedrecombinant human granulocyte colony stimulating factor (lenograstim). Eur. J. Cancer 30A, S7-11. |
8 | Pandit, J., A. Bohm. J. Jancarik, R. Halenbeck, K. Koths, and S. Kim. 1992. Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. Science 258, 1358-1362. DOI |
9 | Parham, P. 2009. The Immune system, 3 eds, Garland Science, New York, NY. |
10 | Procopio, G., M. Niger, and I. Testa. 2011. Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. Neurol. Sci. [Epub ahead of print]. |
11 | Ria, R., T. Gasparre, G. Mangialardi, A. Bruno, G. Iodice, A. Vacca, and F. Dammacco. 2010. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 45, 277-281. DOI ScienceOn |
12 | Keating, G. 2011. Lenograstim: a review of its use in chemotherapy- induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization. Drugs 71, 679-707. DOI ScienceOn |
13 | Crawford, J., D. Dale, and G. Lyman. 2004. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228-237. DOI ScienceOn |
14 | Brandt, S., W. Peters, S. Atwater, J. Kurtzberg, M. Borowitz, R. Jones, E. Shpall, R. Bast, Jr, C. Gilbert, and D. Oette. 1988. Effect of recombinant human granulocyte-macrophage colony- stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 318, 869-876. DOI ScienceOn |
15 | Cooper, K., J. Madan, S. Whyte, M. Stevenson, and R. Akehurst. 2011. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11, 404. DOI |
16 | Cowling, G. and T. Dexter. 1992. Erythropoietin and myeloid colony stimulating factors. Trends Biotechnol. 10, 349-357. DOI |
17 | Diederichs, K., S. Jacques, T. Boone, and P. Karplus. 1991. Low-resolution structure of recombinant human granulocyte- macrophage colony stimulating factor. J. Mol. Biol. 221, 55-60. DOI |
18 | Gervais, V., A. Zerial, and H. Oschkinat. 1997. NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor. Eur. J. Biochem. 247, 386-395. DOI ScienceOn |
19 | Hill, C., T. Osslund, and D. Eisenberg. 1993. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. USA 90, 5167-5171. DOI ScienceOn |
20 | Hoglund, M. 1998. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? Med. Oncol. 15, 229-233. DOI |
21 | Walter, M., W. Cook, B. Zhao, R. Jr. Cameron, S. Ealick. R. Jr. Walter, P. Reichert, T. Nagabhushan, P. Trotta, and C. Bugg. 1992. Crystal structure of recombinant human interleukin- 4. J. Biol. Chem. 267, 20371-20376. |
22 | Sorgel, F., H. Lerch, and T. Lauber. 2010. Physicochemical and biologic comparability of a biosimilar granulocyte colony- stimulating factor with its reference product. BioDrugs 24, 347-357. DOI ScienceOn |
23 | Souza, L., T. Boone, J. Gabrilove, P. Lai, K. Zsebo, D. Murdock, V. Chazin, J. Bruszewski, H. Lu, K. Chen, J. Barendt, E. Platzer, M. Moore, R. Mertelsmann, and K. Welte. 1986. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232, 61-65. DOI |
24 | Wadhwa, M., C. Bird, M. Hamill, A. Heath, P. Matejtschuk, and R. Thorpe. 2011. The 2nd International Standard for human granulocyte colony stimulating factor. J. Immunol. Methods 367, 63-69. DOI |
25 | Zink, T., A. Ross, K. Luers, C. Cieslar, R. Rudolph, and T. Holak. 1994. Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein. Biochemistry 33, 8453-8463. DOI ScienceOn |
26 | Zsebo, K., A. Cohen, D. Murdock, T. Boone, H. Inoue, V. Chazin, D. Hines, and L. Souza. 1986. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 172, 175-184. DOI |
27 | Nagata, S., M. Tsuchiya, S. Asano, Y. Kaziro, T. Yamazaki, O. Yamamoto, Y. Hirata, N. Kubota, M. Oheda, and H. Nomura. 1986. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319, 415-418. DOI ScienceOn |
28 | Nagata, S., M. Tsuchiya, S. Asano, O. Yamamoto, Y. Hirata, N. Kubota, M. Oheda, H. Nomura, and T. Yamazaki. 1986. The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J. 5, 575-581. |
29 | Klumpp, T., K. Mangan, S. Goldberg, E. Pearlman, and J. Macdonald. 1995. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J. Clin. Oncol. 13, 1323-1327. |
30 | Kindt, T., R. Goldsby, B. Osborne, and J. Kuby. 2007. The Immune System. 6th eds. Chapter 2. W.H. Freeman, New York, NY. |
31 | Kuderer, N., D. Dale, J. Crawford, L. Cosler, and G. Lyman. 2006. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106, 2258-2266. DOI ScienceOn |
32 | Lieschke, G., D. Grail, G. Hodgson, D. Metcalf, E. Stanley, C. Cheers, K. Fowler, S. Basu, Y. Zhan, and A. Dunn. 1994. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737-1746. |
33 | Lu, H., C. Clogston, L. Narhi, L. Merewether, W. Pearl, and T. Boone. 1992. Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli. Characterization of the disulfide-reduced intermediates and cysteine-serine analogs. J. Biol. Chem. 267, 8770-8777. |
34 | Martin-Christin, F. 2001. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 12, 185-191. DOI ScienceOn |
35 | McQuaker, I., A. Hunter, S. Pacey, A. Haynes, A. Iqbal, and N. Russell. 1997. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with ymphoproliferative disorders: evidence for clinical and economic benefit. J. Clin. Oncol. 15, 451-457. |
36 | Anderlini, P. 2009. Effects and safety of granulocyte colony- stimulating factor in healthy volunteers. Curr. Opin. Hematol. 16, 35-40. DOI ScienceOn |
37 | Hughes, W., D. Armstrong, G. Bodey, E. Bow, A. Brown, T. Calandra, R. Feld, P. Pizzo, K. Rolston, J. Shenep, and L. Young. 2002. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34, 730-751. DOI ScienceOn |
38 | Aapro, M., J. Bohlius, D. Cameron, L. Dal Lago, J. Donnelly, N. Kearney, G. Lyman, R. Pettengell, V. Tjan-Heijnen, J. Walewski, D. Weber, and C. Zielinski. 2011. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy- induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 47, 8-32. |